Success Metrics

Clinical Success Rate

90.0%

Based on 9 completed trials

Completion Rate

90%(9/10)

Active Trials

3(15%)

Results Posted

22%(2 trials)

Terminated

1(5%)

Phase Distribution

Ph phase_1

Ph phase_2

15%

Ph not_applicable

20%

Ph phase_3

15%

Ph phase_4

45%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution20 total trials

Phase 1Safety & dosage

1(5.0%)

Phase 2Efficacy & side effects

3(15.0%)

Phase 3Large-scale testing

3(15.0%)

Phase 4Post-market surveillance

9(45.0%)

N/ANon-phased studies

4(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(9)

Terminated(1)

Other(6)

Detailed Status

Completed9

unknown6

Recruiting3

Enrolling by invitation1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

90.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (5.0%)

Phase 23 (15.0%)

Phase 33 (15.0%)

Phase 49 (45.0%)

N/A4 (20.0%)

Trials by Status

enrolling_by_invitation15%

unknown630%

terminated15%

recruiting315%

completed945%

Recent Activity

3 active trials

Showing 5 of 20

recruitingphase_2

Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia

NCT03865290

recruitingphase_4

Clinical Trials (20)

Showing 20 of 20 trials

NCT03865290Phase 2

Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia

Recruiting

NCT05844501Phase 4

Ondansetron for the Management of Atrial Fibrillation

Recruiting

NCT07068230Phase 4

Ondansetron and Dexamethasone for Prevention of PDPH, Nausea, and Vomiting

Completed

NCT05065567Phase 3

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Terminated

NCT06850740Not Applicable

Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy

Enrolling By Invitation

NCT05620641Phase 3

Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy

Completed

NCT06297499Phase 1

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

Recruiting

NCT06697782Phase 4

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

Completed

NCT06153602Not Applicable

Effectiveness of Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in TURP Surgery

Completed

NCT03056482Phase 4

Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)

Completed

NCT05881486Not Applicable

Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery

Unknown

NCT05342818Phase 2

Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron

Completed

NCT05583214Phase 4

Evaluating the Effectiveness of Ondansetron Versus Dexamethasone Versus Placebo for the Control of Intraoperative Nausea and Vomiting in Patients Undergoing Lower-segment Caesarean Section Under Spinal Anesthesia

Unknown

NCT05127876Phase 4

Ephedrine Versus Ondansetron During Cesarean Delivery

Completed

NCT04870541Phase 4

Nefopam Versus Ondansteron for Prevention of Post Spinal Shivering.

Unknown

NCT03931863Phase 3

The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section

Unknown

NCT03297021Phase 4

Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting

Completed

NCT04294992Not Applicable

Granisteron Versus Ondansetron for Prophylaxis Against Post-Spinal Anesthesia Shivering: a Randomized Controlled Study

Unknown

NCT03833999Phase 4

Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea

Completed

NCT03530007Phase 2

Anti-shivering Effect of Ondansetron

Unknown

All 20 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 20